JPWO2020072357A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072357A5 JPWO2020072357A5 JP2021543970A JP2021543970A JPWO2020072357A5 JP WO2020072357 A5 JPWO2020072357 A5 JP WO2020072357A5 JP 2021543970 A JP2021543970 A JP 2021543970A JP 2021543970 A JP2021543970 A JP 2021543970A JP WO2020072357 A5 JPWO2020072357 A5 JP WO2020072357A5
- Authority
- JP
- Japan
- Prior art keywords
- hypertonic solution
- composition
- stromal
- antibody
- influx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000000819 hypertonic solution Substances 0.000 claims 16
- 229940021223 hypertonic solution Drugs 0.000 claims 16
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 230000003710 glymphatic flow Effects 0.000 claims 5
- 238000003384 imaging method Methods 0.000 claims 5
- 230000004941 influx Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003703 cisterna magna Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 150000002605 large molecules Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000003712 lysosome Anatomy 0.000 claims 1
- 230000001868 lysosomic effect Effects 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024064529A JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741295P | 2018-10-04 | 2018-10-04 | |
| US62/741,295 | 2018-10-04 | ||
| PCT/US2019/053808 WO2020072357A1 (en) | 2018-10-04 | 2019-09-30 | Improvement of glymphatic delivery by manipulating plasma osmolarity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064529A Division JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022508609A JP2022508609A (ja) | 2022-01-19 |
| JPWO2020072357A5 true JPWO2020072357A5 (https=) | 2022-06-08 |
| JP2022508609A5 JP2022508609A5 (https=) | 2022-06-08 |
| JP7611149B2 JP7611149B2 (ja) | 2025-01-09 |
Family
ID=68502006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543970A Active JP7611149B2 (ja) | 2018-10-04 | 2019-09-30 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
| JP2024064529A Withdrawn JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024064529A Withdrawn JP2024099600A (ja) | 2018-10-04 | 2024-04-12 | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12311035B2 (https=) |
| EP (1) | EP3860564A1 (https=) |
| JP (2) | JP7611149B2 (https=) |
| KR (1) | KR20210100086A (https=) |
| CN (1) | CN113226283A (https=) |
| AU (1) | AU2019354965B2 (https=) |
| CA (1) | CA3115071A1 (https=) |
| WO (1) | WO2020072357A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3188212A1 (en) * | 2020-08-03 | 2022-02-10 | John Pile-Spellman | Devices and methods for trans-arterial osmotic embolization of pathological tissue |
| US20250235554A1 (en) * | 2021-10-25 | 2025-07-24 | Novartis Ag | Methods for improving adeno-associated virus (aav) delivery |
| AU2024220563A1 (en) | 2023-02-16 | 2025-08-14 | University Of Rochester | Improving glymphatic-lymphatic efflux |
| US12483569B2 (en) | 2024-03-28 | 2025-11-25 | Bank Of America Corporation | System and method for identifying unauthorized data traffic in a computing network |
| WO2025250457A1 (en) * | 2024-05-28 | 2025-12-04 | University Of Rochester | Enhanced brain transduction by gene therapeutics |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869248A (en) | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| DE69636937T3 (de) | 1995-12-15 | 2011-01-05 | Virxsys Corp. | Durch trans-spaltung erhaltene therapeutische molekule |
| US6083702A (en) | 1995-12-15 | 2000-07-04 | Intronn Holdings Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| BRPI0108676B8 (pt) | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| EP1429805A4 (en) | 2001-08-17 | 2005-09-21 | Lilly Co Eli | USE OF ANTIBODIES WITH HIGH AFFINITY FOR A $ G (B) PEPTIDE IN THE TREATMENT OF DISEASES AND DISEASES RELATED TO A $ G (B) |
| JP2005503789A (ja) | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Ａβ抗体 |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| EP1613657A2 (en) | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| US8801541B2 (en) | 2007-09-27 | 2014-08-12 | Taylor Made Golf Company, Inc. | Golf club |
| WO2006014638A2 (en) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS |
| BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US20060246075A1 (en) | 2004-09-29 | 2006-11-02 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
| WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| EP1838349A1 (en) | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
| TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| US9370531B2 (en) | 2007-08-31 | 2016-06-21 | New York University | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| SI2453923T1 (sl) | 2009-07-14 | 2016-04-29 | Mayo Foundation For Medical Education And Research | S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere |
| MX350378B (es) | 2012-01-10 | 2017-09-05 | Biogen Ma Inc | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. |
| EP2964270A4 (en) * | 2013-02-21 | 2017-03-22 | University Of Rochester | Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| AU2016206624B2 (en) | 2015-01-14 | 2020-08-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| JP6824535B2 (ja) | 2015-09-11 | 2021-02-03 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳間質内のナノ粒子分布を改善するための組成物および方法 |
| US10123969B2 (en) * | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
| CA3010738A1 (en) * | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| EP3463575B1 (en) * | 2016-06-01 | 2025-03-26 | The University of Virginia Patent Foundation | Methods and compositions for modulating lymphatic vessels in the central nervous system |
| ES2954171T3 (es) * | 2016-07-20 | 2023-11-20 | P&X Medical Nv | Compuestos para su uso en métodos para tratar glaucoma y enfermedades de la retina |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2019
- 2019-09-30 US US17/280,606 patent/US12311035B2/en active Active
- 2019-09-30 AU AU2019354965A patent/AU2019354965B2/en active Active
- 2019-09-30 CA CA3115071A patent/CA3115071A1/en active Pending
- 2019-09-30 JP JP2021543970A patent/JP7611149B2/ja active Active
- 2019-09-30 KR KR1020217013589A patent/KR20210100086A/ko active Pending
- 2019-09-30 EP EP19801124.9A patent/EP3860564A1/en active Pending
- 2019-09-30 CN CN201980075683.8A patent/CN113226283A/zh active Pending
- 2019-09-30 WO PCT/US2019/053808 patent/WO2020072357A1/en not_active Ceased
-
2024
- 2024-04-12 JP JP2024064529A patent/JP2024099600A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508609A5 (https=) | ||
| US12496345B2 (en) | Method of treating cancer | |
| Kumar et al. | Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery | |
| Talegaonkar et al. | Intranasal delivery: An approach to bypass the blood brain barrier | |
| Mittal et al. | Insights into direct nose to brain delivery: current status and future perspective | |
| AU2004248014B2 (en) | Recombinant adeno-associated virus vector for treatment of Alzheimer disease | |
| TWI627954B (zh) | 急性骨髓性白血病（ａｍｌ）之新穎組合治療 | |
| Nair et al. | Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis | |
| US20080305077A1 (en) | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system | |
| Stützle et al. | Nose-to-Brain delivery of insulin for Alzheimer’s disease | |
| JP2009502135A5 (https=) | ||
| US20210069354A1 (en) | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier | |
| JP2020532958A5 (https=) | ||
| RU2002115406A (ru) | Соединение, обладающее свойствами высвобождения гормона роста | |
| US11147873B2 (en) | Treatment of Alzheimer's Disease (AD) with an aluminum salt | |
| US9821023B2 (en) | Methods for the treatment of central nervous system (CNS) disorders and mood disorders | |
| JPWO2020072357A5 (https=) | ||
| Jakki et al. | The blood brain barrier and its role in Alzheimer's therapy: An overview | |
| Wu et al. | Brain delivery strategies for biomacromolecular drugs: intranasal administration | |
| US11857568B2 (en) | Treatment and prevention of Alzheimer's disease (AD) | |
| AU2015219038B2 (en) | Compositions and methods for treating neutropenia | |
| Chen et al. | Intranasal delivering method in the treatment of ischemic stroke | |
| US20180319843A1 (en) | Compositions and methods for treating central nervous system (cns) disorders and mood disorders | |
| JP2014512382A5 (https=) | ||
| Doke et al. | Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers |